Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

BMO Capital Maintains Market Perform on Novartis, Raises Price Target to $116

Author: Benzinga Newsdesk | April 24, 2024 11:03am
BMO Capital analyst Etzer Darout maintains Novartis (NYSE:NVS) with a Market Perform and raises the price target from $114 to $116.

Posted In: NVS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist